Investigating how citrate metabolism affects tumor and immune cells in brain tumors in children
Probing citrate metabolism in tumor and immune cells in diffuse midline gliomas
This study is looking at how certain changes in brain tumors called diffuse midline gliomas affect how the tumors grow and how the immune system responds, with the hope of finding new ways to help kids with this tough condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11029444 on NIH RePORTER |
What this research studies
This research focuses on diffuse midline gliomas (DMGs), aggressive brain tumors in children with poor prognosis. It explores how mutations in histone H3 lead to changes in metabolism, particularly the role of citrate in tumor growth and immune response. By studying patient-derived models, the research aims to understand how citrate influences the immune environment and tumor proliferation. The goal is to identify potential therapeutic targets that could improve treatment outcomes for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with diffuse midline gliomas, particularly those with the H3K27M mutation.
Not a fit: Patients with other types of brain tumors or those without the specific genetic mutations associated with DMGs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the effectiveness of immunotherapy for children with diffuse midline gliomas.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in tumors, suggesting that this approach could yield significant insights and advancements.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Viswanath, Pavithra — University of California, San Francisco
- Study coordinator: Viswanath, Pavithra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.